HCA Healthcare, Inc.

Analysis of HCA Healthcare (HCA)

Technical Analysis HCA exhibits outstanding bullish momentum, trading near its 52-week high with impressive short-term gains. While this proximity suggests limited oversold opportunity, its relatively shallow maximum drawdown over the past year indicates resilient price support during market volatility. The stock's high beta means amplified returns, but also higher sensitivity to market swings.

Fundamental Analysis HCA shows robust revenue growth and expanding profit margins, signaling strong operational execution. Despite high leverage and a current ratio below 1.0, healthy interest coverage and cash flow generation mitigate liquidity concerns. Efficiency metrics like inventory turnover and ROCE reflect competent management of capital and operations.

Valuation & Risk Forward P/E and PEG ratios suggest reasonable valuation relative to earnings growth expectations, though the elevated EV/EBITDA merits peer comparison. Risks include industry-specific factors like regulatory changes and the stock’s inherent volatility, balanced by a lack of significant short interest.

Buy Recommendation HCA presents a compelling case based on strong technical momentum, solid fundamentals, and reasonable forward valuation. Although leverage and volatility require attention, the company’s operational strength and growth trajectory support a positive outlook. For investors comfortable with sector risks and market sensitivity, HCA appears well-positioned for continued performance.

*Note: This is not investment advice, for reference only.*

RockFlow Model Forecast: Three Scenarios for 2026

Based on the provided analysis, here is a 12-month outlook for HCA Healthcare (HCA):

12-Month Outlook for HCA Healthcare (HCA)

Over the next 12 months, HCA is well-positioned to maintain its positive trajectory, driven by strong operational execution, robust revenue growth, and expanding profit margins as key catalysts. Potential risks primarily include the stock's high volatility (beta), sensitivity to broader market swings, and industry-specific headwinds like regulatory changes or shifts in healthcare policy. While a specific analyst target price is not provided, the reasonable forward P/E and positive PEG ratio suggest the current price near 52-week highs has further room for appreciation, contingent on the company maintaining its operational strength and efficient capital management.

* Disclaimer:** This outlook is based on the analysis provided and is for informational purposes only. It is not intended as investment advice.

Wall Street Consensus

Most Wall Street analysts are optimistic about HCA Healthcare, Inc.'s 12-month outlook, with consensus target around $540.29, indicating expected upside potential.

Overall, HCA has investment potential but also faces challenges. Here are key factors to weigh before investing.

HCA has demonstrated exceptionally strong price performance, significantly outperforming the broader market over the recent period. The stock is currently trading near the upper boundary of its yearly range, reflecting robust bullish momentum.

Over the past one and three months, HCA has delivered impressive gains of 12.83% and 17.63%, respectively. With a 3-month relative strength of +17.58% versus the market, the stock has substantially outperformed, and its beta of 1.365 confirms it has been more volatile than the market, amplifying these positive returns.

Currently priced at $540.29, HCA sits within 2.3% of its 52-week high of $552.9, indicating a very strong technical position. While this proximity suggests the stock is not oversold, its relatively shallow maximum drawdown of -14.17% over the past year points to resilient price action even during its peak.

Revenue & Profitability HCA demonstrated solid revenue growth with Q4 2025 revenue reaching $19.5 billion, up from $19.2 billion in Q3. Profitability metrics improved sequentially with net income margin expanding from 8.6% to 9.6%, reflecting better cost management. The company maintained strong operating margins around 16%, indicating stable core operational performance.

Financial Health HCA operates with significant leverage, evidenced by a debt ratio of 83% and total debt to capitalization exceeding 100%. However, the interest coverage ratio of 5.6x demonstrates adequate earnings capacity to service debt obligations. The current ratio below 1.0 indicates potential liquidity constraints, though operating cash flow generation remains robust.

Operational Efficiency Asset utilization appears moderate with an asset turnover of 0.32, while inventory turnover of 6.9 reflects efficient working capital management. The negative return on equity is primarily due to negative shareholder equity, though return on assets of 3.1% and ROCE of 7.2% indicate reasonable operational returns on invested capital.

Valuation Level HCA Healthcare's forward P/E of 14.3 is significantly more attractive than its trailing P/E of 23.2, indicating strong earnings growth expectations. The stock appears reasonably valued from an earnings perspective, a view supported by a PEG ratio slightly below 1.0, which suggests its price is adequately aligned with its projected earnings growth rate.

Peer Comparison A conclusive peer comparison cannot be performed due to the unavailability of industry average data for the provided metrics. The negative P/B ratio is an anomaly, typically resulting from accounting charges that create a negative book value, and its comparison to industry norms would require specific context. The elevated EV/EBITDA multiple of 37.8 warrants further investigation against industry benchmarks to assess its relative valuation.

Volatility Risk HCA's beta of 1.365 indicates higher volatility than the broader market, making it more sensitive to market swings. The 1-year maximum drawdown of -14.17% demonstrates a capacity for significant peak-to-trough declines during adverse market periods.

Other Risks The absence of notable short interest suggests market participants do not harbor significant, widespread bearish sentiment toward the stock. However, investors remain exposed to industry-specific risks, such as potential regulatory changes affecting healthcare providers and fluctuations in patient volumes.